NO944046L - Ökning av medikamentrespons - Google Patents

Ökning av medikamentrespons

Info

Publication number
NO944046L
NO944046L NO944046A NO944046A NO944046L NO 944046 L NO944046 L NO 944046L NO 944046 A NO944046 A NO 944046A NO 944046 A NO944046 A NO 944046A NO 944046 L NO944046 L NO 944046L
Authority
NO
Norway
Prior art keywords
increase
drug response
serotonin
drug
mllnacipran
Prior art date
Application number
NO944046A
Other languages
English (en)
Other versions
NO944046D0 (no
Inventor
David Taiwai Wong
Juan Ignacio Oguiza
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944046D0 publication Critical patent/NO944046D0/no
Publication of NO944046L publication Critical patent/NO944046L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Evnen som fluoxetin, venlafaxin. mllnacipran og duloxetln har til å øke tilgjengeligheten av serotonln, norepinefrin og dopamln, spesielt serotonin, blir forsterket ved administrering i kombinasjon med et medikament som er en serotonin IA reseptor antagonist.
NO944046A 1994-06-16 1994-10-24 Ökning av medikamentrespons NO944046L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26085794A 1994-06-16 1994-06-16
US27746094A 1994-07-19 1994-07-19

Publications (2)

Publication Number Publication Date
NO944046D0 NO944046D0 (no) 1994-10-24
NO944046L true NO944046L (no) 1995-12-18

Family

ID=26948222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944046A NO944046L (no) 1994-06-16 1994-10-24 Ökning av medikamentrespons

Country Status (15)

Country Link
US (6) US5532268A (no)
EP (1) EP0687472A3 (no)
JP (1) JPH083035A (no)
CN (1) CN1113436A (no)
AU (1) AU685510B2 (no)
CA (1) CA2134038C (no)
CO (1) CO4340731A1 (no)
CZ (1) CZ262494A3 (no)
HU (1) HUT71582A (no)
IL (1) IL111380A0 (no)
NO (1) NO944046L (no)
NZ (1) NZ264774A (no)
PE (1) PE28695A1 (no)
PL (1) PL305701A1 (no)
SG (1) SG70562A1 (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
US20060068017A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
FR2746314B1 (fr) * 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
EP0818198A1 (en) * 1996-07-09 1998-01-14 Lilly S.A. Potentiation of drug response by increasing serotonin availability
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
US5958965A (en) * 1996-08-27 1999-09-28 American Home Products Corporation 4-aminoethoxy indoles
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
DE69711519T2 (de) 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
US5830904A (en) * 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2759290B1 (fr) * 1997-02-13 2004-06-18 Pf Medicament Minalcipran pour le traitement de l'incontinence urinaire
FR2759906B1 (fr) * 1997-02-21 2004-06-04 Pf Medicament Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
GB9714675D0 (en) * 1997-07-11 1997-09-17 Smithkline Beecham Plc Novel composition
AU736596B2 (en) * 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
US6037360A (en) * 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
US20030013740A1 (en) * 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
PT1075264E (pt) * 1998-05-08 2005-01-31 Upjohn Co Novas combinacoes farmacologicas de reboxetina e pindolol
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
WO1999061014A2 (en) * 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
ATE449603T1 (de) 1998-09-15 2009-12-15 Lilly Co Eli Verwendung von duloxetine zur behandlung von fibromyalgie
ES2246488T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC Reboxetina para tratar la migraña.
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
PL211402B1 (pl) 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
WO2001032625A1 (en) * 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
DZ3282A1 (fr) * 2000-03-07 2001-09-13 Lilly Co Eli Traitement du psoriasis
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
JP5132864B2 (ja) * 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
DE10042412B4 (de) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US20040030131A1 (en) * 2000-10-04 2004-02-12 Martine Keenan Pharmaceutical compounds
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
US6833377B2 (en) 2001-02-05 2004-12-21 Gevys Pharmaceuticals Ltd. Composition and method for potentiating drugs
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
EP1482921A1 (en) * 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
CA2382419A1 (en) * 2002-04-24 2003-10-24 Le Groupe Lysac Inc. Synergistic blends of polysaccharides as biodegradable absorbent materials or superabsorbents
CN1671368A (zh) * 2002-07-24 2005-09-21 柏树生物科学公司 疼痛继发性抑郁（dsp）的治疗
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004075886A1 (fr) * 2003-02-14 2004-09-10 Pierre Fabre Medicament Utilisation de l’enantiomere (1s, 2r) du milnacipran pour la preparation d’un medicament
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20060111385A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20060111394A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
CN101137648A (zh) * 2005-03-01 2008-03-05 惠氏公司 结晶和非晶4－氰基－n－{(2r)－2－[4－(2,3－二氢－苯并[1,4]二氧杂环己烯－5－基)－哌嗪－1－基]－丙基}－n－吡啶－2－基－苯甲酰胺盐酸盐
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
BRPI0720958A2 (pt) * 2006-12-27 2014-03-18 Lek Pharmaceuticals Omposição de duloxetina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
CN102458123A (zh) * 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2012024397A2 (en) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2959904A1 (en) 2014-06-27 2015-12-30 Institut De Recerca Contra La Leucemia Josep Carreras Methods for treating, diagnosing and prognosing a haematological malignancy
EP3348266A1 (en) 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
NL300886A (no) * 1962-11-23
US3471515A (en) * 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3466325A (en) * 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
DE1668055B2 (de) * 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
GB1308191A (en) * 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
GB8909209D0 (en) * 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives

Also Published As

Publication number Publication date
US5532250A (en) 1996-07-02
CO4340731A1 (es) 1996-07-30
IL111380A0 (en) 1994-12-29
US5538992A (en) 1996-07-23
US5532268A (en) 1996-07-02
AU7742194A (en) 1996-01-04
EP0687472A3 (en) 1997-01-15
NO944046D0 (no) 1994-10-24
US5532264A (en) 1996-07-02
US5552429A (en) 1996-09-03
US5532244A (en) 1996-07-02
AU685510B2 (en) 1998-01-22
CZ262494A3 (en) 1996-01-17
NZ264774A (en) 1997-07-27
HUT71582A (en) 1995-12-28
PL305701A1 (en) 1995-12-27
CA2134038C (en) 1997-06-03
HU9403071D0 (en) 1994-12-28
EP0687472A2 (en) 1995-12-20
SG70562A1 (en) 2000-02-22
CN1113436A (zh) 1995-12-20
CA2134038A1 (en) 1995-12-17
JPH083035A (ja) 1996-01-09
PE28695A1 (es) 1995-10-04

Similar Documents

Publication Publication Date Title
CA2134038A1 (en) Potentiation of Drug Response
Calabrese et al. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
Pergolizzi Jr et al. A review of duloxetine 60 mg once‐daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain
EP0919234A3 (en) Potentiation of pharmaceuticals by moxonidine
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
AU2003289854A1 (en) Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
EA200100748A1 (ru) Ингибиторы обратного захвата моноаминов для лечения расстройств цнс
NO2012015I2 (no) Dapoxetine
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
AR007609A1 (es) Una composicion farmaceutica
EA199800140A1 (ru) Композиции с контролируемым высвобождением пароксетина
AR014012A1 (es) Formula de liberacion prolongada
JP2005523334A5 (no)
GR3034007T3 (en) Potentiation of serotonin response
NO20063809L (no) Belagte minitabletter av venlaflaxin hydroklorid med forlenget virkning
AR055628A1 (es) Dipositivos de administracion transdermicas de farmacos que contienen o- desmetilvenlafaxina (odv) o sus sales
BRPI0518043A (pt) tetraidroisoquinolinas substituìdas por 4-fenila e uso destas para bloquear a recaptação de norepinefrina, dopamina e serotonina
Leonard et al. Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
RU94037967A (ru) Применение флуоксетина, венлафаксина, мильнаципрана и дульоксетина для усиления реакции на лекарственное средство, фармацевтическая композиция на их основе
RU2009101143A (ru) Лечение психологических состояний с применением антаггонистов m1-мускариновых рецепторов
MA30645B1 (fr) Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
Mallarkey Efexor: generic name-venlafaxine
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
BR0114898A (pt) Métodos para modificar o comportamento relacionado com adicção de um mamìfero sofrendo de adicção de pcp, e de melhoria dos efeitos da adicção de pcp
AR041628A1 (es) Uso de moduladores de la recaptacion de norepinefrina para prevenir y tratar los sintomas vasomotores